EUVIMEDEUVIMED entdecken
VergleichsstudieNetzwerk-MetaanalyseSystematische ÜbersichtMetaanalyse

Vonoprazan Versus Lansoprazole in the Healing and Maintenance Phase of Erosive Esophagitis: A Systematic Review and Meta-Analysis of Randomised Controlled Trials

Syed Hasham Ali, Sushil Rayamajhi, Hareesha Rishab Bharadwaj, Aditya Gaur, Muhtasim Fuad, Arkadeep Dhali, Dushyant Singh Dahiya, Matan Bone, Babu Mohan, Sushovan Guha

Digestive Diseases and Sciences · 2025

DOI: 10.1007/s10620-025-09290-7 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Digestive Diseases and Sciences, 2025. Verfasst von Syed Hasham Ali und 9 weiteren Autor:innen. Beteiligte Einrichtung: Dow University of Health Sciences, Karachi, Pakistan. Hauptthemen laut MEDLINE: Esophagitis, Esophagitis, Peptic, Lansoprazole, Proton Pump Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Vonoprazan (VPZ), a potassium-competitive acid blocker, has emerged as an alternative to traditional proton-pump inhibitors like Lansoprazole (LPZ) for the treatment of erosive esophagitis (EE). Vonoprazan provides stronger acid suppression compared to PPIs; however, evidence regarding its effectiveness and safety in treating EE remains limited. We conducted a systematic review and meta-analysis to evaluate the comparative effectiveness and safety of VPZ versus LPZ in the healing and maintenance phases of EE. METHODS: A comprehensive literature search was conducted across PubMed, Embase and Cochrane Library to identify eligible randomized controlled trials (RCTs) published till 12 December 2024 that evaluated efficacy and safety of VPZ and LPZ in patients with EE. Outcomes included endoscopic healing rates, recurrence rates, and treatment-emergent adverse events (TEAEs). Pairwise meta-analyses and network meta-analyses (NMA) were performed using Review Manager 5.4.1 and Bayesian models. RESULTS: This meta-analysis included 7 RCTs with 4,903 patients. In the healing phase, VPZ showed significantly higher endoscopic healing rates than LPZ at Week 2 (RR: 1.09; 95% CI: 1.04-1.13; p < 0.0001, I2 = 0%) and among patients with severe EE (LA classification C/D) at both Week 2 (RR: 1.26; 95% CI: 1.15-1.38; p < 0.00001, I2 = 0%) and Week 8 (RR: 1.13; 95% CI: 1.03-1.24; p = 0.007, I2 = 67%). No significant differences were observed in TEAEs, severe adverse events, or treatment discontinuation. In the maintenance phase, VPZ 20 mg reduced recurrence rates compared to LPZ 15 mg (RR: 0.41; 95% CI: 0.17-0.85) without differences in TEAEs. CONCLUSIONS: VPZ demonstrates greater efficacy in healing and maintaining remission in EE, particularly in severe cases, with a safety profile comparable to LPZ. These findings support VPZ as an effective alternative to PPIs. However, long-term studies are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EsophagitisEsophagitis, PepticLansoprazoleProton Pump InhibitorsPyrrolesSulfonamidesHumansRandomized Controlled Trials as TopicTreatment Outcome

Stichwörter der Autor:innen

Erosive esophagitis (EE)Healing and maintenance phaseLansoprazoleProton pump inhibitors (PPIs)Vonoprazan

Substanzen

1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamineLansoprazoleProton Pump InhibitorsPyrrolesSulfonamides

Autor:innen und Institutionen

  • Dow University of Health Sciences, Karachi, Pakistan.
  • University of Central Florida/HCA Florida West Hospital, Pensacola, FL, USA.
  • Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK.
  • Yeovil District Hospital, Somerset NHS Foundation Trust, Higher Kingston, Yeovil, UK.
  • Academic Department of Gastroenterology, Royal Hallamshire Hospital, Sheffield, UK.
  • Division of Gastroenterology, Hepatology & Motility, The University of Kansas School of Medicine, Kansas City, KS, USA.

Zitieren

APA

Ali, S. H., Rayamajhi, S., Bharadwaj, H. R., Gaur, A., Fuad, M., Dhali, A., Dahiya, D. S., Bone, M., Mohan, B., & Guha, S. (2025). Vonoprazan Versus Lansoprazole in the Healing and Maintenance Phase of Erosive Esophagitis: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-025-09290-7

Vancouver

Ali SH, Rayamajhi S, Bharadwaj HR, Gaur A, Fuad M, Dhali A, et al. Vonoprazan Versus Lansoprazole in the Healing and Maintenance Phase of Erosive Esophagitis: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Digestive Diseases and Sciences. 2025. doi:10.1007/s10620-025-09290-7

BibTeX
@article{Ali2025,
  author = {Ali, Syed Hasham and Rayamajhi, Sushil and Bharadwaj, Hareesha Rishab and Gaur, Aditya and Fuad, Muhtasim and Dhali, Arkadeep and Dahiya, Dushyant Singh and Bone, Matan and Mohan, Babu and Guha, Sushovan},
  title = {Vonoprazan Versus Lansoprazole in the Healing and Maintenance Phase of Erosive Esophagitis: A Systematic Review and Meta-Analysis of Randomised Controlled Trials},
  journal = {Digestive Diseases and Sciences},
  year = {2025},
  doi = {10.1007/s10620-025-09290-7}
}
Kostenlos starten →